Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 10, 2012, Pages 1999-2003

  Barta, Stefan K ^a   Zou, Yiyu ^a   Schindler, John ^b   Shenoy, Niraj ^c   Bhagat, Tushar D ^a   Steidl, Ulrich ^a   Verma, Amit ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c JACOBI MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic; Animal model; Cytarabine; Immunoconjugate; Leukemia; Mouse; NOD; Ricin

Indexed keywords

ANTILEUKEMIC AGENT; COMBOTOX; CYTARABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY CD22; RICIN A; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; CELL LINE, TUMOR; CYTARABINE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED NOD; NEOPLASM STAGING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RICIN; SIALIC ACID BINDING IG-LIKE LECTIN 2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865734833     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.679267     Document Type: Article

References (35)

1. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRCUKALL12/ECOG2993 study. Blood 2007;109:944-950.
2. Faderl S, O'Brien S, Pui C-H, et al. Adult acute lymphoblastic leukemia. Cancer 2010;116:1165-1176.
3. FitzGerald DJ, Wayne AS, Kreitman RJ, et al. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300t-6309.
4. Schindler J, Sausville E, Messmann R, et al. The toxicity of deglycosylated ricin Achain-containing immunotoxins in patients with non-Hodgkin ' s lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res 2001;7:255-258.
5. Messmann RA, Vitetta ES, Headlee D, et al. Aphase Istudy of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin Achain (dgA) and IgG-RFB4-dgA(Combotox) in patients with refractory CD19 (-), CD22 (-) Bcell lymphoma. Clin Cancer Res 2000;6:1302-1313.
6. Jegalian AG, Wayne AS, Kreitman RJ, et al. CD22 expression in pediatric B-lineage acute lymphoblastic leukemia. Blood 2009;114(SUPPL. 1): Abstract 4119.
7. May RD, Vitetta ES, Moldenhauer G, et al. Selective killing of normal and neoplastic human Bcells with anti-CD19-and anti-CD22-ricin Achain immunotoxins. Cancer Drug Deliv 1986;3:261-272.
8. Herrera L, Bostrom B, Gore L, et al. Aphase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. JPediatr Hematol Oncol 2009;31:936-941.
9. Topp MS, Zugmaier G, Goekbuget N, et al. Report of a phase IItrial of single-agent BiTE(R) antibody blinatumomab in patients with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL). Blood 2009;114(SUPPL. 1): Abstract 840.
10. Topp MS, Kufer P, Gö kbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. JClin Oncol 2011;29:2493-2498.
11. Dominietto A, Raiola AM, Van Lint MT, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br JHaematol 2001;112:219-227.
12. Jabbour E, O'Brien S, Thomas D, et al. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). JClin Oncol 2011;29(SUPPL.): Abstract 6507.
13. Schindler J, Gajavelli S, Ravandi F, et al. Aphase Istudy of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br JHaematol 2011;154:471-476.
14. Herrera L, Farah RA, Pellegrini VA, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-Bacute lymphoblastic leukemia cells in vitro. Leukemia 2000;14:853-858.
15. Ghetie MA, Podar EM, Gordon BE, et al. Combination immunotoxin treatment and chemotherapy in SCIDmice with advanced, disseminated Daudi lymphoma. Int JCancer 1996;68:93-96.
16. Herrera L, Stanciu-Herrera C, Morgan C, et al. Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-Bacute lymphoblastic leukemia. Leuk Lymphoma 2006;47:2380-2387.
17. Griffin TC, Weitzman S, Weinstein H, et al. Astudy of rituximab and ifosfamide, carboplatin, andetoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children ' s Oncology Group. Pediatr Blood Cancer 2009;52:177-181.
18. Coiffier B, Lepage E, Briere J, et al. CHOPchemotherapy plus rituximab compared with CHOPalone in elderly patients with diffuse large-B-cell lymphoma. NEngl JMed 2002;346:235-242.
19. Pfreundschuh M, Trü m per L, Ö s terborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
20. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008;113:117-125.
21. Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVACwith rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and " unclassifiable" highly aggressive B-cell lymphoma. Br JHaematol 2012;156:234-244.
22. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVADplus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.
23. Raponi S, Stefania De Propris M, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098-1107.
24. Ghetie M-A, May RD, Till M, et al. Evaluation of ricin Achaincontaining immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 1988;48:2610-2617.
25. Herrera L, Yarbrough S, Ghetie V, et al. Treatment of SCID/human Bcell precursor ALLwith anti-CD19 and anti-CD22 immunotoxins. Leukemia 2003;17:334-338.
26. de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicinconjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012;26:255-264.
27. Liu X-Y, Pop LM, Tsai L, et al. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-Bacute lymphoblastic leukemia cell lines. Int JCancer 2011;129:497-506.
28. Dreier T, Baeuerle PA, Fichtner I, et al. Tcell costimulusindependent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human Bcell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. JImmunol 2003;170:4397-4402.
29. Stanciu-Herrera C, Morgan C, Herrera L. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in pre-Bacute lymphoblastic leukemia cell lines. Leuk Res 2008;32:625-632.
30. Advani A, Gundacker H, Sala-Torra O, et al. Southwest Oncology Group study S0530: a phase 2 trial of clofarabine/cytarabine for relapsed/refractory acute lymphocytic leukemia. Blood 2009;114(SUPPL. 1): Abstract 3094.
31. Larson RA, Dodge RK, Linker CA, et al. Arandomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGBstudy 9111. Blood 1998;92:1556-1564.
32. Ludwig W-D, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-Bacute lymphoblastic leukemia: results of the German multicenter trials GMALL03/87 and 04/89. Blood 1998;92:1898-1909.
33. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALLtrial: MRCUKALLXII/ECOGE2993. Blood 2005;106:3760-3767.
34. Ribera J, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMAALL-93 trial. Haematologica 2005;90:1346-1356.
35. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. JClin Oncol 2011;29:532-543.